Lipid MK16
Version 1.034a8760 · 2026-09-13
| CAS No. | Not available |
| Chemical Name | Lipid MK16 |
| Synonyms | Lipid-MK16, MK 16, MK-16, MK16 BL |
| SMILES | CC(OCCCCCC)OCCCCCCN(CCCCCCOC(C)OCCCCCC)CCCCCCNC(CC[C@H]1CC[C@@](C2=CC(F)=CC=C2F)(S(C3=CC=C(Cl)C=C3)(=O)=O)CC1)=O |
| Formula | C55H91ClF2N2O7S |
| M.Wt | 997.84 |
| Purity | ELSD-HPLC>95% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Wang C, Xue Y, Markovic T, et al. Blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system. Nature Materials. 2025;24:1653-1663. |
MK16 is an MK-0752-derived ionizable lipid developed for blood-brain-barrier-crossing mRNA delivery in preclinical mouse models. In the cited MK16 BLNP formulation, the authors reported an apparent LNP pKa of 6.86, a particle diameter of 137.0 ± 4.1 nm, 84.8 ± 1.5% mRNA encapsulation, and brain FLuc expression 8.3-fold above an MC3 LNP comparator after intravenous administration. The study also reported mRNA expression in neurons, astrocytes, brain capillary endothelial cells and microglia, as well as proof-of-concept results in cocaine-conditioned-place-preference and orthotopic glioblastoma models. All formulation and performance information shown below is literature-derived study evidence, not a product specification or a guarantee of reproducible LNP performance.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →